Potent antagonists of somatostatin: synthesis and biology.
The search for synthetic analogues of somatostatin (SRIF) which exhibit selective affinities for the five known receptor subtypes (sst1-5) has generated a large number of potent agonist analogues. Many of these agonists display good subtype selectivities and affinities for the subtypes 2, 3, and 5, with very few selective for sst1 or sst4. Until the recent report by Bass and co-workers (Mol. Pharmacol. 1996, 50, 709-715; erratum, Mol. Pharmacol. 1997, 51, 170), no true antagonists had been discovered, let alone any displaying differential receptor subtype selectivity. In this present study, we explore the effect of this putative L5,D6 antagonist motif on various series of somatostatin agonist analogues, both linear and cyclic. It was found that many D5,L6 agonists could be converted into competitive antagonists by applying this motif, the most potent of which was H-Nal-cyclo[DCys-Pal-DTrp-Lys-Val-Cys]-Nal-NH2 (32). This antagonist was selective for hsst2 with an affinity of 75 nM and an IC50 of 15.1 nM against SRIF-14 in a rat in vitro antagonist bioassay. Receptor-selective somatostatin antagonists should provide valuable tools for characterizing the many important physiological functions of this neuropeptide.
Hocart
S J
SJ
Peptide Research Laboratories, Tulane University School of Medicine, New Orleans, Louisiana 70112, USA.
Jain
R
R
Murphy
W A
WA
Taylor
J E
JE
Morgan
B
B
Coy
D H
DH
D000818:Animals; D016466:CHO Cells / Q000187:drug effects / Q000378:metabolism; D006224:Cricetinae; D010455:Peptides / Q000138:chemical synthesis* / Q000494:pharmacology*; D010456:Peptides, Cyclic / Q000138:chemical synthesis* / Q000494:pharmacology*; D051381:Rats; D013004:Somatostatin / Q000037:antagonists & inhibitors*
C111676:Nal-cyclo(cysteinyl-1-oxohexadecyl-tryptophyl-lysyl-valyl-cysteinyl)-2-naphthylamide; D010455:Peptides; D010456:Peptides, Cyclic; D013004:Somatostatin